82 related articles for article (PubMed ID: 14973300)
41. Sodium oxybate: a review of its use in the management of narcolepsy.
Robinson DM; Keating GM
CNS Drugs; 2007; 21(4):337-54. PubMed ID: 17381187
[TBL] [Abstract][Full Text] [Related]
42. Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons.
Goodwin AK; Griffiths RR; Brown PR; Froestl W; Jakobs C; Gibson KM; Weerts EM
Psychopharmacology (Berl); 2006 Nov; 189(1):71-82. PubMed ID: 17047936
[TBL] [Abstract][Full Text] [Related]
43. Gamma-hydroxybutyrate and ethanol effects and interactions in humans.
Thai D; Dyer JE; Benowitz NL; Haller CA
J Clin Psychopharmacol; 2006 Oct; 26(5):524-9. PubMed ID: 16974199
[TBL] [Abstract][Full Text] [Related]
44. Potential gamma-hydroxybutyric acid (GHB) drug interactions through blood-brain barrier transport inhibition: a pharmacokinetic simulation-based evaluation.
Bhattacharya I; Boje KM
J Pharmacokinet Pharmacodyn; 2006 Oct; 33(5):657-81. PubMed ID: 16941233
[TBL] [Abstract][Full Text] [Related]
45. Involvement of gamma-hydroxybutyrate (GHB) and GABA-B receptors in the acute behavioral effects of GHB in baboons.
Goodwin AK; Froestl W; Weerts EM
Psychopharmacology (Berl); 2005 Jul; 180(2):342-51. PubMed ID: 15739078
[TBL] [Abstract][Full Text] [Related]
46. Spontaneous and precipitated withdrawal after chronic intragastric administration of gamma-hydroxybutyrate (GHB) in baboons.
Weerts EM; Goodwin AK; Griffiths RR; Brown PR; Froestl W; Jakobs C; Gibson KM
Psychopharmacology (Berl); 2005 May; 179(3):678-87. PubMed ID: 15645222
[TBL] [Abstract][Full Text] [Related]
47. [Integrated treatment of the symptoms of narcolepsy-cataplexy syndrome with sodium oxybate].
Poza-Aldea JJ
Rev Neurol; 2009 Jan 1-15; 48(1):27-31. PubMed ID: 19145563
[TBL] [Abstract][Full Text] [Related]
48. Sodium oxybate: new drug. Fewer attacks of cataplexy in some patients.
Prescrire Int; 2007 Jun; 16(89):98-101. PubMed ID: 17582923
[TBL] [Abstract][Full Text] [Related]
49. Ultra-high-performance liquid chromatography tandem mass spectrometry determination of GHB, GHB-glucuronide in plasma and cerebrospinal fluid of narcoleptic patients under sodium oxybate treatment.
Tittarelli R; Pichini S; Pedersen DS; Pacifici R; Moresco M; Pizza F; Busardò FP; Plazzi G
Forensic Sci Int; 2017 May; 274():70-74. PubMed ID: 28139340
[TBL] [Abstract][Full Text] [Related]
50. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy.
Sleep; 2002 Feb; 25(1):42-9. PubMed ID: 11833860
[TBL] [Abstract][Full Text] [Related]
51. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy.
Xyrem International Study Group
J Clin Sleep Med; 2005 Oct; 1(4):391-7. PubMed ID: 17564408
[TBL] [Abstract][Full Text] [Related]
52. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy.
Black J; Pardi D; Hornfeldt CS; Inhaber N
Sleep Med; 2009 Sep; 10(8):829-35. PubMed ID: 19616998
[TBL] [Abstract][Full Text] [Related]
53. The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients.
Borgen LA; Okerholm RA; Lai A; Scharf MB
J Clin Pharmacol; 2004 Mar; 44(3):253-7. PubMed ID: 14973300
[TBL] [Abstract][Full Text] [Related]
54. Sodium oxybate for cataplexy.
Lemon MD; Strain JD; Farver DK
Ann Pharmacother; 2006 Mar; 40(3):433-40; quiz 581-2. PubMed ID: 16507620
[TBL] [Abstract][Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
